Debt to equity ratio has decreased and is lowest in last five years
Tremendous increasing trend in total sale last 3 year
Tremendous increasing in Book Value last 3 year
Company Earning excess return
Steady View
Annual Net Profit in last 3 years is trending up
Steady increase in Total Assets for last 3 Years
EBITDA is continuously increasing for last 3 Years
Company financial liquidity has improved
Good Return On Capital Employed of 13.47
Good Return on Equity of 17.11% is achieved by the company
Risky View
Tsr Growth Index - Poor Score of 27.79
Very Low Dividend Yield of 0.440 %
Low Earning Yield of 5.01 %
EPS decline for last four quarters
Terrific Steady Risky Stock View - Fundamental Snapshot
Share Overview
Promoter Owned
58.70 %
Institution Owned
19.10 %
Public/Others
22.20 %
Outstanding Shares
9.22 Cr
Floating Shares
3.64 Cr
Floating / Outstanding
39.46%
Book Value/Share
98.18
Face value
2.00
Share Holding
Annual Key Income Statement of INDOCO
Period
31_Mar_2022
31_Mar_2021
Growth
Net Income From Continuing Ops
154.80
93.05
66.36 %
Net Income
154.80
93.05
66.36 %
Operating Income
248.38
157.46
57.74 %
Total Revenue
1540.75
1218.61
26.44 %
Operating Expense
1255.35
701.51
78.95 %
Interest Expense
16.46
21.04
21.77 %
Tax Expense
81.77
38.95
109.94 %
Income Before tax
236.57
132.00
79.22 %
Gross Profit
1083.96
858.97
26.19 %
Dividend Paid
-13.79
-2.79
394.27 %
Quarterly Key Income Statement of INDOCO
Period
31_Dec_2022
30_Sep_2022
Growth
Net Income From Continuing Ops
28.15
49.73
43.39 %
Net Income
28.14
49.73
43.41 %
Operating Income
44.87
87.85
48.92 %
Total Revenue
399.20
433.04
7.81 %
Operating Expense
337.16
345.19
2.33 %
Interest Expense
7.01
5.25
33.52 %
Tax Expense
10.07
17.57
42.69 %
Income Before tax
38.22
67.30
43.21 %
Gross Profit
268.85
305.65
12.04 %
Dividend Paid
0
-0.0400
100.00 %
Key Balance Sheet Fields
Period
31_Mar_2022
31-Mar-21
Growth
Common Stock
18.43
18.43
0 %
Current Liabilities
424.85
406.92
4.41 %
Total Liabilities
581.45
546.07
6.48 %
Current Assets
773.62
622.53
24.27 %
Total Assets
1486.09
1315.06
13.01 %
Working capital
348.77
215.61
61.76 %
Accounts Payable
133.29
113.23
17.72 %
Inventory
310.52
237.85
30.55 %
Net Receivable
298.68
235.39
26.89 %
Key Cash Flow Fields
Period
31_Mar_2022
31_Mar_2021
Growth
Cash EPS
22.32
18.03
23.79 %
Cash From Investment Activity
-121.41
-66.69
82.05 %
Cash From Financial Activity
-44.37
-29.87
48.54 %
Cash Operational Activity
173.83
82.22
111.42 %
Net Cash Flow
8.05
-14.34
156.14 %
NetIncome
154.80
93.05
66.36 %
Capital Expenditure
125.32
76.85
63.07 %
Change To Inventory
-72.66
-29.53
146.05 %
About Indoco Remedies Limited Indoco Remedies Limited manufactures, markets, and sells formulations and active pharmaceutical ingredients in India and internationally. The company's products portfolio includes respiratory products, such as Karvol Plus, Febrex Plus, Dropizin, and Tuspel; stomatologicals products that include Sensodent-K, Sensoform Toothpaste, Sensoform Gum Paint, Rexidin M, Rexidin SRS, RR Sensoform Dental, Sensodent-KF, Poviclean, Rexidin, Sensodent-R, Snowdent, Kidodent, Rexidin Plus, and Dentogel; gastrointestinal products, such as Carmicide, Cyclopam, Cyclopam Plus, Cyclomeff, and Nosic; pain/analgesics products that include Lignox A and Lignox ; and ophthal/otologicals products, such as Renolen, Homide, Dexoren " S, Zincoren, Bfloren, Dexoren, Otorex, Mofloren-D, Mofloren " BF, Macuchek, and Mofloren LP. It also provides vitamins/minerals/nutrients that include Methycal, Cital UTI, SM Fibro, Coloferrin, Cal Aid, and MCBM DHA; urology products, such as Cital-H and Cital; Cloben G, Noxa, and Scabex for dermatology; ATM, Clygan, Vepan, and Oxipod for anti-infectives; Hemsyl for blood related therapies; MCBM 69 and D-Chiro for gynecological; Aloja and Aloja M for Anti-Diabetics; and Spear for anti-haemorrhoidal. In addition, the company provides analytical services, such as impurity profile, particle size analysis, heavy metal analysis, polymorphism and compatibility studies, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and validation services. Further, it offers architectural design, lighting, mechanical and utility engineering, project and construction management, electrical, control system, piping, structural design, data transfer system, and process engineering. The company was formerly known as Indo Continental Trading Company. Indoco Remedies Limited was founded in 1945 and is based in Mumbai, India.
TSR Tech Strength is based on Deep Analysis, Back Testing and Historical Trend Analysis using Machine Learning. Overall Technical Strength is based on 50+ indicators including Technicals, moving Avg, chart patterns, candlestick and proprietary algorithms.Technical Strength is calculate from 5Mins Ticck to One Month Tick
TSR Growth analyses dozen of Historical , MRQ, TTM parameters, returns of Individual Stocks vis-a-vis sector , broad based Index to access Growth Potential
TSR Value analyses dozen of Historical , MRQ, TTM parameters, returns of Individual Stocks vis-a-vis sector , broad based Index to access its value
This is an automated process and in NO WAY should be considered as a tip as its based on past data. We strongly recommend to use these signals for information only and seek advise from a certified professional for any trading decision.If you like it then please share. The more the visitors the more the innovations. Feedback
We are working on fundamental strength also. Please share your views to help shape up the requirement.
